Protocol Ledger

NCT04501978 · Phase III · COMPLETED

ACTIV-3: Therapeutics for Inpatients With COVID-19

Interventional Phase III clinical trial protocol NCT04501978 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-04 Enrollment: 2,753 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04501978
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2,753 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04501978
Protocol FieldVerified Registry Value
NCT IdentifierNCT04501978
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment2,753 participants (ACTUAL)
Registered Start Date2020-08-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04501978
Hospital Research SiteLocationSite Profile
USC Norris Comprehensive Cancer Center and Keck MedicineLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI